Elite Pharmaceuticals Files 8-K

TL;DR

Elite Pharma filed a routine 8-K, check for any material updates.

AI Summary

Elite Pharmaceuticals, Inc. filed an 8-K on November 18, 2024, reporting information under Regulation FD and including financial statements and exhibits. The filing does not detail specific financial transactions or events but serves as a routine corporate disclosure.

Why It Matters

This filing indicates Elite Pharmaceuticals is making a required disclosure to the SEC, which could contain updates on corporate events or financial information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K disclosure and does not appear to contain any immediately alarming information.

Key Players & Entities

• ELITE PHARMACEUTICALS, INC. (company) — Registrant
• Nevada (jurisdiction) — State of incorporation
• 001-15697 (filing_id) — Commission File Number
• 22-3542636 (tax_id) — IRS Employer Identification No.
• 165 Ludlow Avenue, Northvale, New Jersey 07647 (address) — Principal executive offices
• 2017502646 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01. R

Filing Documents

• form8-k.htm (8-K) — 36KB
• ex99-1.htm (EX-99.1) — 8KB
• ex99-1_001.jpg (GRAPHIC) — 37KB
• 0001493152-24-046525.txt ( ) — 267KB
• eltp-20241118.xsd (EX-101.SCH) — 3KB
• eltp-20241118_lab.xml (EX-101.LAB) — 33KB
• eltp-20241118_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 18, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC . (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 165 Ludlow Avenue , Northvale , New Jersey 07647 (Address of principal executive offices) (201) 750-2646 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01. Regulation FD Disclosure On November 18, 2024, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it received approval from the US Food and Drug Administration (FDA) on November 15, 2024, for a generic version of Vyvanse (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. Lisdexamfetamine Dismesylate belongs to a class of drugs known as central nervous systems (CNS) stimulants and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This product will be marketed and sold under the Elite Laboratories, Inc. label. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite's filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 18, 2024 ELITE PHARMACEUTICALS, INC. By: /s/ Nasrat Hakim Nasrat Hakim, President and CEO

View Full Filing

View this 8-K filing on SEC EDGAR